Asklepios Klinik Weissenfels
Hospital
Location:
Weissenfeld,
Germany (DE)
ISNI: 0000000404639215
ROR: https://ror.org/040f4cr30
Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase (2020)
Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, et al.
Conference contribution
Nilotinib Vs Nilotinib Plus Pegylated Interferon a (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response (2019)
Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Brummendorf TH, Rosee PL, Heim D, et al.
Conference contribution
Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer (2019)
Wiesmüller F, Kopke J, Aust D, Roy J, Dahl A, Pilarsky C, Grützmann R
Journal article
Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018)
Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al.
Conference contribution